By Ed Lin
Compugen /zigman2/quotes/207656860/composite CGEN -2.17% (ticker: CGEN)
The drug and diagnostic company saw shares rocket 62% on news that Compugen reached a collaboration agreement with Pfizer /zigman2/quotes/202877789/composite PFE +1.25% (ticker: PFE). The pact covers the predictive discovery by Compugen of therapeutic peptide product candidates for "three drug targets of interest to Pfizer."
Cintas /zigman2/quotes/201631915/composite CTAS -1.10% (CTAS)
Disappointing second-quarter results sent shares of the uniform maker tumbling 11%. Barrington Research analyst Alexander Paris Jr. maintained a Market Perform rating on Cintas but trimmed estimates. "The company continues to operate under very difficult economic conditions as its customer base has continued to reduce its headcount," Paris wrote in a research report.
Achillion Pharmaceuticals /zigman2/quotes/227285072/composite ACHN -16.67% (ACHN)
Upbeat analyst commentary lifted the company's stock by 9.4%. Roth Capital Partners analyst Edward Nash initiated coverage of Achillion at Buy with a $12 price target. "Achillion, we believe, is the strongest value-play currently in the HCV (hepatitis-C virus) therapeutic space," Nash wrote.
Shares of the drug developer surged 42% on upbeat results from two Phase III trials of the investigative drug Iluvien for diabetic macular edema, a cause of vision loss associated with diabetic retinopathy.
The charts record the net change in share price, the high, low and closing trades, and share volume for companies with noteworthy stock activity last week. In addition, the graphs depict last week's daily price activity in detail. The dotted line on some graphs denotes the stock's 200-day moving average; lack of a moving average means the shares have traded for less than that time period.
The smaller charts record the daily movement in 15-minute intervals.
Comments? E-mail us at firstname.lastname@example.org